SCHEMBL3755332

SCHEMBL3755332

CS(=O)(=O)c1ccc(Cn2nc(C(=O)Nc3ccc(S(C)(=O)=O)cc3)c3ccccc32)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.54
MEN1 O00255 1/20 0.54
KMT2A Q03164 1/20 0.54
PTGER4 P35408 7/20 0.53
MCL1 Q07820 1/20 0.51
IDH1 O75874 1/20 0.49
CNR1 P21554 1/20 0.49
GAA P10253 1/20 0.48
MAPK1 P28482 1/20 0.48
ROCK1 Q13464 2/20 0.47
HDAC3 O15379 1/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC2 Q92769 1/20 0.46
HDAC10 Q969S8 1/20 0.46
HDAC8 Q9BY41 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
NCOR2 Q9Y618 1/20 0.46
POLB P06746 1/20 0.46
ELANE P08246 1/20 0.46
PTGDR2 Q9Y5Y4 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3428395 0.97 PTGER4 (0.54) KDM4EMEN1KMT2APTGER4MCL1
SCHEMBL3428570 0.96 KDM4E (0.51) KDM4EMEN1KMT2APTGER4MCL1
SCHEMBL3411563 0.96 ELANE (0.51) KDM4EMEN1KMT2APTGER4MCL1
SCHEMBL3428006 0.96 PTGER4 (0.57) KDM4EMEN1KMT2APTGER4MCL1
SCHEMBL3429031 0.96 MEN1 (0.51) KDM4EMEN1KMT2APTGER4MCL1
SCHEMBL3430198 0.96 KDM4E (0.51) KDM4EMEN1KMT2APTGER4MCL1
SCHEMBL3428417 0.95 PTGER4 (0.57) KDM4EMEN1KMT2APTGER4MCL1
SCHEMBL3430295 0.94 KMT2A (0.49) KDM4EMEN1KMT2APTGER4MCL1
SCHEMBL3430253 0.93 KDM4E (0.49) KDM4EMEN1KMT2APTGER4MCL1
SCHEMBL3426970 0.93 KDM4E (0.49) KDM4EMEN1KMT2APTGER4MCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 US claimed
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 US disclosed
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 US disclosed
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 US disclosed
WO-2009121623-A2 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY SUMMIT CORPORATION PLC (GB) 2009-10-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY CPT1B, SMN1; SMN2, GYS1 KDM4E 1965/4885MEN1 3958/4885KMT2A 2516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.